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Abstract
The management of a patient placed on extracorporeal membrane oxygenation (ECMO)
is a team effort. The anesthesiology team plays an integral part during cannulation and
oftentimes as well during decannulation. In addition, the management of a patient taken
to the operating room on ECMO requires a degree of expertise. This chapter will review
monitors, echocardiography, medications, fluid and blood management protocols, and
ventilation strategies to help the anesthesiology team provide best care for this patient
population.
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1. Introduction
The anesthetic management of patients on extracorporeal membrane oxygenation (ECMO)
continues to evolve as the indication for ECMO use expands. The anesthesiology team has to
care for these patients during the critical period prior to ECMO placement, during cannula‐
tion, for surgeries while on ECMO, and then finally during decannulation. A keen understand‐
ing of the physiology, pharmacokinetics, and pharmacodynamics of the patient on ECMO is
needed in order to appropriately care for this delicate patient population.
2. Monitoring
2.1. Invasive blood pressure monitoring
Mean arterial pressure (MAP) should be monitored during ECMO with an invasive blood
pressure catheter. End‐organs typically require a MAP greater than 65 mmHg in order to
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
maintain an adequate perfusion pressure. Hypotension may be corrected by increasing ECMO
flows and/or administering volume. If the hypotension is secondary to a decreased systemic
vascular resistance, then vasopressor agents may be needed to increase MAP.
There should be a degree of pulsatility even while on higher levels of ECMO support. Lack of
pulsatility may point toward stagnation, which can cause overdistension of the left ventricle
(LV) and lead to thrombosis. LV decompression is imperative to prevent ventricular ischemia
and allow ventricular recovery. In these cases, ECMO flow can be reduced, or a vasodilator
may be administered to attempt afterload reduction or inotropic agents may be added [1]. If
the LV is not adequately decompressed, a left‐heart vent, a percutaneous left ventricular assist
device (LVAD; Impella®, Abiomed Corp., USA), or a balloon atrial septostomy can be
performed to decompress the LV [2, 3]. Decreased pulsatility may also be a sign of hypovole‐
mia, a mechanical obstruction, right ventricular failure, and/or dysrhythmias [1].
2.2. Interpretation of arterial blood gases from different anatomical sites
The location of the arterial inflow cannula determines the best site for arterial blood sampling
and/or monitoring of SpO2. With axillary cannulation, radial artery catheters should be
avoided on the ipsilateral side, as the values obtained are not reflective of the net gas exchange
[1]. With femoral cannulation, the right radial artery should be monitored. If heart function is
poor, then arterialized blood flow to the coronary and cerebral circulations will occur through
retrograde flow in the aorta. As heart function begins to recover, the mixing point within the
aorta travels distally, and perfusion will be provided by the native cardiac output. The degree
of oxygenated perfusion will also be determined by lung function, with poor lung function in
the setting of good cardiac output leading to poorly oxygenated blood being supplied to the
coronary and upper body circulations. Placement of a radial artery catheter on the right will
allow detection of this condition, referred to variably as Harlequin syndrome, North–South
syndrome, or upper body hypoxemia [1].
If the patient is on venovenous (VV) ECMO, the infusion blood will mix with the systemic
venous return blood. The typical ratio of infusion to deoxygenated blood is approximately 3:1.
As a result, blood analysis will demonstrate approximately a PO2 40, PCO2 41, and saturation
of 80% [4]. A minimum saturation of 80% is adequate to support systemic oxygen delivery as
long as the hematocrit is greater than 40% and cardiac function is decent [4]. As the lung begins
to recover, the saturation will increase over 80%.
If the patient is on veno‐arterial (VA) ECMO, the infusion blood will mix with the blood in the
aorta. This leads to a typical ratio of infusion to native blood of 8:1 [4]. If lung function is normal,
then blood analysis will demonstrate approximately a PO2 of 200, PCO2 of 40, and saturation
of 100% (on FiO2 of 0.2) [4]. If there is no native lung function, then PO2 will be approximately
half at 100.
2.3. Mixed venous blood saturation and other hemodynamic monitors
An arterial oxygen saturation (SaO2) greater than 80% may be sufficient to monitor appropriate
systemic oxygen delivery during ECMO [5, 6]. SaO2 alone, though, may not always be a suitable
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monitor, as various variables including hemoglobin, degree of recirculation, membrane
oxygenator function, extracorporeal blood flow to cardiac output ratio, and venous oxygen
saturation contribute to systemic oxygen delivery (DO2) and oxygen consumption (VO2) [7].
Systemic perfusion is best measured by mixed venous blood saturation (SVO2), with a goal to
maintain it greater than 75% [4]. If mixed venous saturation is less than 75%, then pump flow
may need to be increased or volume may need to be given in the form of blood and/or
crystalloid solution.
Pulmonary artery catheters (PACs) can be difficult to place once ECMO has been initiated and
may not be a valuable monitor. The minority of blood flows through the lungs while on ECMO,
and SvO2 from a PAC will probably not be accurate. SvO2 can be estimated however by blood
gas analysis or saturation probe at the level of the venous cannula leading to the membrane
oxygenator [1]. Other markers of anaerobic metabolism such as lactate may be useful to
monitor when SvO2 appears to be inaccurate [8].
Central venous pressure (CVP) can be used as a trend monitor as ECMO flow also affects exact
measurements of this monitor. A rising CVP pressure due to mechanical obstructive processes
such as tension pneumothorax, tamponade, or abdominal compartment syndrome can be
detected with a central venous catheter.
Newer flow‐based hemodynamic monitoring devices such as the FlotracTM and NICOMTM
(Edward life sciences, USA) are currently being investigated in the ECMO patient popula‐
tion.
2.4. Cerebral oximetry
A high percentage of ECMO patients unfortunately suffer a neurological complication. These
complications can run the gamut from seizure, intracranial hemorrhage, ischemic stroke to
encephalopathy [9]. Neurological complications increase the rate of mortality [10]. Methods
to monitor for neurological complications include electroencephalogram, transcranial Dop‐
pler, and cerebral oximetry.
Upper body hypoxemia can be detected by a decrease in cerebral oximetry values, either
unilateral or bilateral. A differential cerebral desaturation may occur when the right brain
becomes hypoxemic, but perfusion of the left brain is preserved because of retrograde
oxygenated blood flow from the descending aorta [11]. Central aortic saturation may be
improved by increasing venous drainage, increasing blood oxygen content, and/or placing
additional outflow arterial cannulas.
3. Echocardiography for ECMO
In ECMO‐supported patients, soft‐tissue ultrasound for vascular access guidance, transthora‐
cic (TTE) and transesophageal (TEE) cardiac ultrasound are complementary technologies that
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can guide safe cannula placement, initiate therapy, monitor progress of therapy, detect
complications, and help determine ultimate recovery and weaning strategies.
3.1. ECMO patient selection
A comprehensive TEE or TTE is important to help guide therapy in critically ill adults who
may benefit from ECMO therapy. Patients may demonstrate refractory hypoxemia, despite
maximal ventilator support or hemodynamic instability even with resuscitative efforts.
Echocardiography can identify potentially reversible pathological states, which may account
for the patient's hypoxic or hemodynamic condition. Findings may include tamponade, acute
severe mitral or aortic insufficiency, severe pulmonary hypertension, intracardiac shunts, and/
or severe right or left ventricular dysfunction. Alternative resuscitative maneuvers may be
undertaken before ECMO is initiated to alleviate potentially reversible conditions. Significant
conditions identified by echocardiography that may complicate VV or VA ECMO include a
prominent patent foramen ovale, atrial septal defect (ASD), intra‐atrial septal aneurysm, pacer
and defibrillator leads, or tricuspid valvular disease. Echocardiography may also provide
information regarding aortic dissections, which is a contraindication to VA ECMO. Finally,
echocardiography allows prompt assessment of cardiac function to guide VV versus VA
ECMO therapy.
3.2. Echocardiography for cannulation
Surface ultrasound guides the correct placement of guidewires and cannulas into vessels
within the neck, thorax, axillary and/or femoral areas, and into their final correct positions
within the right atrium (RA) and inferior vena cava (IVC) to allow proper flow and limit
recirculation between cannulas [12–14]. TEE can be used to guide central versus peripheral
arterial cannula placement. Prior to placement of the arterial cannula, echocardiography
should exclude a preexisting aortic dissection, which is a contraindication to VA ECMO. After
placement, echocardiography should evaluate the aorta for an iatrogenic dissection, which
may be a complication of the cannulation and initiation sequence. All cannulas should be
properly placed before initiating ECLS to optimize initiation time and eliminate repositioning,
which introduces bleeding and infection risk.
Echocardiography also allows confirmation of proper positioning of the single Avalon Elite®
Bi‐Caval Dual Lumen catheter (Maquet Holding, Germany), which is inserted typically via the
right internal jugular vein (IJ), but may be inserted via the left IJ if the right side is inaccessible
[13]. The cannula body should span the RA and encompass both the superior vena cava (SVC)
and IVC for drainage. The return lumen should be positioned in the center of the RA and
directed to allow return flow of oxygenated blood to cross the tricuspid valve. Utilization of
saline microbubble contrast through specific lumens of the dual lumen catheter may help guide
correct placement and orientation within the RA in relation to the tricuspid valve [15].
Comparison of dual‐lumen cannulation to conventional cannulation for VV ECMO demon‐
strated that dual‐lumen cannulation required more materials, more technical and physician
experience, and higher costs, but allowed better patient mobilization, including prone
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positioning and potentially lighter sedation and shorter duration of mechanical ventilation
[16].
Use of the Avalon Elite® bi‐caval dual lumen catheter has also been described in adults with
secundum ASDs and Eisenmenger's syndrome as a bridge to recovery or transplant. The right
atrial infusion port is positioned echocardiographically to infuse oxygenated blood across the
ASD as opposed to the traditional tricuspid valve position. Placement improves oxygenation,
decreases pulmonary artery pressure, and unloads the right ventricle. Patients without an ASD
who have pulmonary hypertension or Eisenmenger's syndrome requiring VV ECMO may
benefit by having an atrial blade septostomy performed prior to bicaval cannula placement
[17].
TTE can also be utilized to place and monitor the position of the Avalon Elite® using the
subcostal sagittal plane view, which provides imaging of the RA and both venae cavae. All
three of the catheter ports can be identified and confirmed in their correct anatomical locations
using TTE. A survey demonstrated that TEE (67%) was utilized more frequently to place the
Avalon Elite® catheter than TTE (25%) or fluoroscopy (4%) with a mean insertion and
orientation time of 26 ± 13 min [18]. It is recommended during the initial provider training
period that placement of the Avalon Elite® Bi‐Caval dual‐lumen catheter occurs under both
fluoroscopy and TEE guidance. As proficiency with cannula placement improves, TEE alone
provides excellent image guidance for correct placement and orientation [14].
3.3. ECMO maintenance
On VV ECMO, venous cannula malposition, with inflow and outflow cannula positioned in
close proximity leads to recirculation of returned oxygenated blood back to the ECMO pump.
Recirculation undermines effective treatment and occurs with both single‐lumen and dual‐
lumen cannulas. Traditionally, two‐dimensional (2D) and three‐dimensional (3D) echocar‐
diography with confirmation of proper venous cannula position were used to exclude
significant recirculation. Research using dilution techniques with ultrasonic probes attached
to the arterial inlet and venous outlet lines of the cannulas allows calculation of a recirculation
percent. Surveillance TTE with serial quantification of the recirculation percent can help
determine malposition and diagnose cannula migration [19].
On VA ECMO, echocardiography can be utilized to define myocardial contractility, left
ventricular end diastolic volume (LVEDV), mitral regurgitation, aortic valve systolic excur‐
sion, and LV decompression. For patients supported with VV or VA ECMO, volume manage‐
ment is critical to prevent volume overload and worsening lung injury. A positive fluid balance
on hospital day 3 has been shown to be an independent predictor of 90‐day mortality in patients
supported with either VA or VV ECMO [20]. In a study evaluating utilization of echocardiog‐
raphy to guide fluid therapy optimization, measurements of LV stroke volume using the aortic
valve area and aortic velocity time integral were performed at baseline. Passive leg raise was
then performed with elevation of the lower extremities to a 45‐degree angle, while the trunk
was lowered from a semirecumbent to a supine position. Repeat measurement of LV stroke
volume was then performed, and an increase in 10% or greater of the passive leg raise stroke
volume (PLRSV) from baseline predicted a greater than 15% increase in stroke volume after
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volume expansion (500 ml saline administered over 15 min). This simple diagnostic procedure
can reliably identify patients with ARDs supported with VV ECMO who may benefit from
fluid loading [21].
3.4. Detection of extracorporeal life support complications
Patients supported by ECMO are at increased risk for complications due to their underlying
critical illness and the complex support techniques being utilized. Complications that may
occur during ECMO that can be diagnosed by echocardiography include thrombosis, cannula
malposition, tamponade, SVC or IVC syndrome, RV overload, hepatic congestion, and/or
cannula thrombus casting [2, 22].
3.5. Recovery and weaning
Evaluating pulmonary and ventilator parameters help identify pulmonary recovery for
patients on VV ECMO. Estimation of cardiac or cardiopulmonary recovery can be more
complicated for VA ECMO. Historical metrics include a left ventricular ejection fraction (LVEF)
of greater than 35–40%, right ventricular ejection fraction (RVEF) greater than 40% in the
absence of moderate‐to‐severe tricuspid regurgitation, LV outflow tract velocity time integral
greater than 10 cm, and/or the absence of LV dilatation with serial decreases in the ECMO flow
rate. Multiple weaning protocols have been published, but ultimately ECMO flow is gradually
decreased by set amounts, with periods of full support for recovery between trials. During the
weaning phase, serial comprehensive echocardiographic examinations with a focus on
qualitative and quantitative measures of RV and LV function can help guide the weaning
process. Other more sophisticated applications of echocardiography to assess LV function
during ECMO weaning include two‐dimensional strain rate and Doppler tissue myocardial
velocities [23].
TTE can be utilized to evaluate suitability for weaning, although contrast‐enhanced TTE may
be necessary to improve image quality. While contrast microspheres are hydrodynamically
labile and demonstrate increased bubble destruction with passage through the ECMO circuit,
the reduced signal persistence does not typically impair adequate image optimization with
contrast‐enhanced TTE [2].
Weaning protocols using a continuous hemodynamic TEE (hTEE®; Imacor, Garden City, NY)
have been described to successfully manage separation of patients from ECMO in the ICU.
The benefit of the hTEE® over conventional TEE or TTE is device placement and utilization
in a continuous fashion over the 4–6 h weaning period, allowing multiple assessments and
interventions over time. Timely determination of ventricular function recoverability is critical,
secondary to the significant resources involved in caring for these complex, critically ill
patients. Patients who demonstrate a low likelihood of ventricular recovery may have ECMO
discontinued or transitioned to a longer term support solution, such as a LVAD or cardiac
transplantation.
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4. Drug administration
4.1. Pharmacokinetics and pharmacodynamics
The body's relationship between the drug dosage and the drug concentration over time is
pharmacokinetics (PK). Pharmacodynamics (PD) is the relationship between drug concentra‐
tion and the associated pharmacological response. PK and PD are linked via the dose–effect
relationship. The goal of drug therapy is to maximize efficacy and minimize toxicity. Critical
illness and ECMO alter the PK and PD of medications significantly, and therefore, the risk of
therapeutic failure or toxicity is heightened in this patient population [24, 25]. Clearance of
medications in critically ill patients is typically dependent upon renal or hepatic function, and
clearance can increase or decrease depending upon the underlying disease process [26].
Complex changes in PK parameters occur with ECMO initiation and maintenance with an
increased volume of distribution, altered clearance, and sequestration of drugs in the ECMO
circuitry [27]. Failure to account for these alterations in PK can lead to therapeutic failure, and
drug monitoring is critical for appropriate treatment outcomes when feasible.
ECMO alters the PK of sedative, analgesic, and antibiotic drugs, and their metabolites,
independent of other associated patient and pathological factors. Drug molecular size, degree
of ionization, lipophilicity, and plasma protein binding, all contribute significantly to adult,
pediatric, and neonatal ECMO PK studies. Drugs with a high lipophilicity or protein binding
have greater degradation or loss in the ECMO circuitry [25, 27–30]. Significant sequestration
occurs primarily in the oxygenator due to its large surface area. The type and age of the
components (oxygenator, pump, and tubing) also contribute to the degree of sequestration [25,
31].
4.2. Sedatives and analgesics
Sedatives and analgesics are necessary in the critically ill ECMO patients to provide optimal
and safe care. A balance between light sedation and avoidance of muscle relaxants and the
specific needs of the ECMO patient needs to be considered. Deeper sedation with muscle
relaxants may be needed to optimize flows and ventilation strategies and minimize oxygen
consumption. Adequate sedation minimizes catheter movement and dislodgements, and
prevents patient coughing, which can create a “suck down” event and lowers ECMO flows
and may cause hemolysis [25]. ECMO patients typically undergo total IV anesthesia during
surgery with anesthetic agents including sedatives, hypnotics, analgesics, and muscle relax‐
ants. Clinical teams with expertise in infusion therapy and total IV anesthetic techniques can
be helpful to guide therapy and prevent underdosage or overdosage of medications. Signifi‐
cant and rapid increases in midazolam, morphine, and propofol doses immediately after
ECMO initiation may be necessary to maintain pre‐ECMO sedation levels. These “supranor‐
mal” elevations may be required for the entire ECMO support period and may warrant
additional neuromonitoring to ensure adequate sedation levels [32, 33]. A survey of interna‐
tional ECMO centers identified that medications were used in the following frequencies:
midazolam (79%), fentanyl (45%), morphine (43%), dexmedetomidine (41%), propofol (36%),
and clonidine (25%) [33]. Muscle relaxants were used in only 35% of centers, and differences
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in sedation and neuromuscular blocking agent use varied between experienced and less
experienced centers. Critical care best practices can be extended to ECMO patients who should
have consideration of daily cessation of sedation, analgesics, and avoidance of neuromuscular
blockade.
Due to longer recognized indications for ECMO support in newborn patients compared to
adults, most of the studies of PK exist in this patient population. Due to differences in physi‐
ology and circuit design between newborns and adults, translation of studies between patient
populations may not be applicable [34]. Large PK studies in adult patients on ECMO focused
upon antibiotics, antifungals, antivirals, sedatives, and analgesics are currently being per‐
formed [35, 36].
Variability in studies regarding drug sequestration in neonates exists for both morphine and
fentanyl, and some advocate morphine use over fentanyl due to reduced drug withdrawal and
length of stay in morphine‐treated patients [25, 37, 38]. In vitro modeling has demonstrated
that the tubing and membrane oxygenator of the ECMO circuit extract 67% of fentanyl over
48 h, but morphine demonstrated no extraction; therefore, higher fentanyl dosing but not
morphine is needed to maintain adequate plasma levels [38]. Other in vitro studies examining
morphine and fentanyl demonstrated significant sequestration of both agents by the ECMO
circuit with 40% dose extraction by the PVC and membrane oxygenator [31, 39]. Some
recommend using fentanyl for short‐term pain relief and to avoid long‐term fentanyl use in
ECMO patients due to significant uptake by the tubing. Morphine may also be affected by
uptake and may not be the best agent for long‐term pain relief. IV acetaminophen, with lower
lipophilicity and protein binding, may prove to bind less to the circuit components. An in vitro
study of IV acetaminophen concentration over 6 h demonstrated relatively constant concen‐
trations over time, irrespective of circuit age [40]. Based upon this study, use of IV acetami‐
nophen in place of opioids may be preferable in patients requiring analgesia, undergoing
ECMO therapy.
Pharmacokinetic and dynamic studies of midazolam in newborns supported with ECMO
demonstrate an increase in the volume of distribution and an increased clearance of midazolam
and its active metabolite 1‐hydroxymidazolam. Over time, the active 1‐hydroxymidazolam
accumulates and may contribute to a greater proportion of the sedative effects seen clinically.
The clinical significance of the active metabolite is unclear, because typically after 5–7 days of
ECMO, infusion rates of midazolam need to be increased substantially to maintain sedation
levels despite accumulation of the active metabolite. Others are concerned that 1‐hydromida‐
zolam accumulates and must be accounted for when the infusion is discontinued and the
sedative effect remains. Careful titration based upon sedation scores are recommended to
guide sedative therapy [41]. In vitro experiments demonstrate that sequestration is higher in
older circuits than newer circuits and suggest that sequestration may be a time‐dependent
process. This phenomenon, in conjunction with increased clearance, contributes to the need to
increase drug doses over time [25]. Benzodiazepines, as a class, demonstrate sequestration
with 46–89% of midazolam and 50–59% of a dose of lorazepam being extracted by the PVC
tubing and membrane oxygenator in a time‐dependent fashion [31, 38, 39, 42].
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Dexmedetomidine has demonstrated decreases in concentrations over time during in vitro
ECMO analysis related to PVC circuit adsorption, and dosing adjustments to maintain
appropriate serum concentrations are recommended [43]. Use of propofol in patients on
ECMO has been debated over concerns of propofol damaging the ECMO circuit or membrane
oxygenator. For cardiac surgical cases, it is not recommended to administer propofol directly
into the cardiopulmonary bypass circuit with a membrane oxygenator due to poor blood
mixing and propofol separation in the reservoir [44]. Administration is recommended via a
dedicated peripheral intravenous line as opposed to a central line to prevent prompt venous
cannula uptake and direct routing to the pump. Despite theoretical concerns, injection of
propofol into the pump does not cause alteration in gas exchange nor oxygenation to patients
on cardiopulmonary bypass [45]. Use of propofol in patients on ECMO has been debated.
Propofol, a highly lipophilic medication, demonstrates significant sequestration with up to
98% concentration loss due to tubing binding, which limits drug efficacy [46]. Propofol‐
induced hypertriglyceridemia with associated hemolysis has been reported in ECMO patients
[47]. Surveys indicate that propofol use for sedation is not common and may stem from
concerns regarding poor mixing and poor gas exchange from the oxygenator, despite these
findings not having been found specifically in ECMO patients [33]. Propofol may be utilized
in patients on ECMO, but concerns regarding extremely high dose requirements, limited effect,
propofol infusion syndrome, hypertriglyceridemia, and hemolysis exist.
4.3. Antibiotics
Antibiotics are commonly given to patients on ECMO for surgical prophylaxis and/or to treat
the underlying pathology of the respiratory failure or associated infection occurring during
the critical illness. Bloodstream infections are common in ECMO patients, occurring in 14.4%
of patients supported for greater than 48 h, with Gram‐negative bacilli being the most frequent
pathogen [48]. The success of ECMO may rely on the success of the antibiotic therapy, and
therapeutic failure secondary to inadequate drug concentrations must be avoided. PK features
and dosing requirements of vancomycin, cephalosporins, and carbapenems are unclear with
some studies suggesting significant sequestration with resultant lower concentrations, while
others suggesting no change in concentration in ECMO patients [31, 42, 49, 50]. Antifungal
agents, caspofungin and voriconazole, have been studied, with caspofungin demonstrating
maintained peak and trough levels but voriconazole being significantly sequestrated. Limited
data exist for antivirals; there is no significant change in concentration across the oxygenator
for oseltamivir given for influenza A infections to ECMO patients [51]. For patients with H1N1
disease, standard dosing of enteral oseltamivir in ECMO patients is recommended and
produces concentrations necessary to inhibit the neuraminidase activity of the H1N1 virus [52].
Therapeutic drug monitoring is recommended for all antibiotics, antifungals, and antivirals
when available, and is critical to guide therapy to optimize outcomes [25].
4.4. Inotropes and vasopressors
ECMO is initiated for a variety of life‐threatening respiratory or cardiac issues, and can be used
to support patients and organ recovery for extended periods of time. Many patients are
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critically ill when ECMO is initiated and are supported with cardiovascular adjuncts (96.2%)
prior to ECMO support, including inotropes (95.8%), vasopressors (83.5%), IABP (40.1%),
cardiopulmonary resuscitation/defibrillation (31.1%), and ventricular assist devices (9.0%) [9].
Patients who were on cardiovascular adjuncts at the initiation of ECMO have a worse outcome
than patients not supported on these agents [9]. Pharmacological agents are typically required
to provide support to recovering organs during the weaning and separation phases, as these
organs are still recovering from recent intervention and/or injury. Weaning of ECMO occurs
commonly in the intensive care unit or the operating room and requires collaboration of a team
of professionals. Hemodynamic instability in the separation phase may be secondary to
vasodilation, RV or LV dysfunction, left ventricular outflow tract obstruction, pulmonary
hypertension, respiratory failure, and/or acidosis. Specific therapy should be initiated prior to
separation to improve weaning and separation success rates, as failed weaning is associated
with organ injury or failure [53]. Predictors of successful weaning are improved pulse pressure,
decreased inotropic score, and improved LVEF and RVEF.
5. Anticoagulation
5.1. Heparin
Initiation of ECMO requires the consideration of anticoagulation and associated risk of
bleeding versus thrombosis due to blood exposure to nonnatural surfaces. Exposure of blood
to the artificial surfaces of the ECMO circuits initiates a complex inflammatory response and
the coagulation pathway. Multiple biochemical pathways are activated, which lead to
procoagulant activity as well as fibrinolytic activity, which can lead to circuit thrombosis and
patient hemorrhage. Unfractionated heparin is the most widely used anticoagulant and works
via two endogenous anticoagulants—antithrombin (AT) and tissue factor pathway inhibitor
(TFPI). A survey of 121 ECMO centers determined that unfractionated heparin is the preferred
anticoagulant for most cases and that alternative anticoagulants are used only 8% of the time
[54].
Standard anticoagulation protocols for VV and VA ECMO include a bolus of unfractionated
heparin (2500–5000 IU) administered intravenously during guidewire placement immediately
prior to cannulation. After ECMO institution, heparin is administered via a central line by
continuous infusion to maintain an ACT between 180 and 220 s. Small case series, however,
suggest that lower goal ACT values between 140 and 160 s lead to less major bleeding and
bleeding‐induced death and transfusions without an increase in oxygenator changeovers or
thrombotic events [55].
Studies have investigated ECMO patients supported without anticoagulation in order to
minimize bleeding complications. In one study of 32 patients (24 post cardiotomy, 8 eCPR) on
VA ECMO without anticoagulation during maintenance of ECMO, no neurologic or hemor‐
rhagic complications occurred [56]. In certain high‐risk patients for hemorrhagic complications
supported on ECMO, it may be reasonable to withhold systemic anticoagulation during VA
ECMO. VV ECMO patients may also tolerate no anticoagulation, as a case report described a
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successful 32‐day heparin‐free VV ECMO support period for a patient who suffered a
retroperitoneal hematoma during initial cannulation [57]. Another case report described a
weaning strategy in a patient on VV ECMO who required cessation of heparin therapy due to
persistent thoracic and mediastinal bleeding by maintaining a normal blood flow (62.5 ml/kg/
min) and weaning the gas flows only [58]. Based upon these small series of studies, interruption
or cessation of systemic anticoagulation may be considered if necessary to manage bleeding
risk.
Bleeding is a common complication in ECMO patients, occurring in up to 22–32% of patients
[59]. In the presence of hemorrhage, or traumatic bleeding, heparin may be held temporarily
to control bleeding sources. Patients with traumatic brain injury have historically been a
relative contraindication due to concerns about anticoagulation and intracranial bleeding. Two
published case reports indicate that these patients may be managed successfully on ECMO
with low‐dose anticoagulation (heparin 2000 unit bolus at initiation) and goal aPTT of 40–60
s [60]. Although studies are small, historical contraindications such as severe septic shock,
traumatic brain injury, polytrauma patients, pregnancy, and patients requiring frequent
surgical intervention are now being treated with ECMO without full‐dose anticoagulation and
broadening the indications for ECMO significantly [61–65].
Patients on ECMO may require surgery, with tracheostomy, extremity, and vascular and
abdominal exploration being the most common procedures performed. Heparin infusions may
be held during the surgical procedure and immediately resumed postoperatively. Postopera‐
tively, ECMO patients requiring noncardiac surgery have been shown to have statistically
significant higher blood transfusion requirements (73.3 vs. 25.5%), higher average number of
units transfused (2.8 vs. 0.8%), and higher perioperative mortality (46.7 vs. 6.4%) in comparison
to LVAD patients undergoing similar noncardiac surgical procedures [66]. The use of blood
products increases mortality in both ECMO and LVAD patients undergoing noncardiac
surgery, and meticulous surgical technique, interrupting anticoagulation, and minimizing
blood transfusions may improve overall mortality. Mortality may be decreased if 81 mg of
aspirin is continued preoperatively in both ECMO and LVAD patients undergoing noncardiac
surgery.
5.2. Direct thrombin inhibitors
Bivalirudin (Angiomax®, The Medicines Company, USA) has been proposed as an alternative
anticoagulant to heparin for patients on ECMO. According to guidelines, ECMO patients with
heparin‐induced thrombocytopenia (HIT) should be anticoagulated with direct thrombin
inhibitors (DTIs) such as bivalirudin or argatroban [67]. Dosing of bivalirudin for ECMO
patients ranges from 0.025 to 0.5 mg/kg/h, although no standard dose exists due to limited use.
Monitoring of the anticoagulation effect for patients on DTIs is difficult, with ACT, aPTT, and
ecarin clotting time all being recommended [68]. A retrospective study of 21 patients (12 adults
and 9 children) undergoing postcardiotomy ECMO receiving heparin versus bivalirudin
demonstrated a better coagulation profile, less bleeding and less transfusions, and overall
lower costs in the bivalirudin group [69]. In this study, bivalirudin‐treated patients had
significantly longer ACT, aPTT, and TEG®r times at different specific time intervals. A study
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comparing aPTT in patients receiving heparin versus bivalirudin on VV and VA ECMO
demonstrated more frequent aPTT variations greater than 20% of the previous value in the
heparin‐treated group [70]. Based upon these variations, the number of drug dose corrections
was higher in the heparin‐treated group. Although not statistically significant, both major and
minor bleeding were higher in the heparin group. Bivalirudin may be superior to heparin due
to more consistent aPTT levels with less drug dose alterations.
Avoidance of blood stagnation with bivalirudin anticoagulation is critical due to a short half‐
life and rapid cleavage of bivalirudin by proteolytic enzymes. This may lead to inadequate
anticoagulation and increased risk of thrombosis, especially in stagnant flow areas. Cardiac
chambers can become natural reservoirs for stagnant flow on ECMO when chambers are
enlarged, and poor cardiac function limits forward cardiac flow. In bivalirudin‐anticoagulated
patients, echocardiography findings of a dilated atrium, poor ventricular function, and/or no
aortic valve opening are concerning and increase the risk of thrombosis. If present, partial
ECMO, institution of improved drainage, venting, or inotropic support should be performed
urgently. If unsuccessful, conversion to a different anticoagulant should occur [71].
Argatroban (Argatroban, GlaxoSmithKline, USA), a DTI, is also indicated as an anticoagulant
for prophylaxis or treatment of thrombosis in patients with HIT. In vitro analysis of circuits
primed with argatroban suggests that thrombin generation may be lower [72]. Utilization in
patients undergoing VV ECMO was studied in nine patients with the suspicion of HIT, eight
of which were also on renal replacement therapy [73]. The first patient received argatroban
infusion of 2 mcg/kg/min as recommended in the product information. Significant bleeding
requiring transfusion occurred in this patient, and the subsequent eight patients received 0.2
mcg/kg/min continuous infusions to minimize bleeding. This dosing was sufficient to increase
the aPTT and thrombin time (TT) to goal within 4 h in the majority of the patients. In this small
study, the maintenance dose of argatroban was 0.15 mcg/kg/min, and no adjustment in dosing
was necessary for patients in renal failure. It is recommended that dosages of argatroban
should be decreased in the critically ill patients, patients with hepatic dysfunction, and ECMO
patients. Several successful case reports using full‐dose argatroban dosing in patients with HIT
exist, but adequacy of standard anticoagulation monitoring remains a concern [74–76]. DTIs
can be used safely in patients on ECMO, but limited experience and concern over a consistent
monitor of adequacy of anticoagulation limit widespread acceptance of these agents for all
ECMO patients. Currently, DTIs are typically reserved for patients with severe AT‐III defi‐
ciency or HIT.
5.3. Heparin‐induced thrombocytopenia
HIT is a complication of heparin therapy with a mortality of 10–30%. Antibodies bind to a
complex of heparin and platelet factor 4 and cause thrombocytopenia and thrombosis. Within
4–5 days of heparin exposure, platelet counts fall but symptoms may present sooner in patients
who have been previously exposed to heparin. If HIT is suspected, discontinuation of heparin
should occur, and continuation of anticoagulation with an alternative agent should be
considered to prevent thrombosis. As thrombocytopenia is common in critically ill patients
due to a variety of other illnesses, HIT should be ruled out by lab testing with PF4 ELISA
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analysis [73]. A study of 119 patients supported on ECMO demonstrated that by day 4, 60%
of the patients had a 50% or greater decrease in platelet counts [77]. In patients suspected of
having HIT (19%), a reduction of platelet count by 71% was present with a median platelet
count of 43 × 109/l. One patient had laboratory‐confirmed HIT; yet, all patients suspected of
having HIT, warranting a change in anticoagulation therapy, demonstrated a higher hospital
mortality rate (61 vs. 32%).
Once HIT is suspected, unfractionated heparin should be stopped and conversion to a
nonheparin anticoagulant should be considered. Warfarin should be avoided until thrombo‐
cytopenia resolves, and prophylactic platelet transfusions should not be administered. DTIs
or factor Xa inhibitors should be used for anticoagulation. Bivalirudin is the recommended
agent for patients with HIT requiring urgent cardiac surgery and ECMO [67, 78]. Recom‐
mended dosing for ECMO is 0.5 mg/kg/h IV, which is closer to the thrombosis prophylaxis
dose of 0.25 mg/kg/h versus the bypass‐dosing regimen (1.75–2.5 mg/kg/h). A short half‐life
and absence of renal or hepatic clearance make bivalirudin a preferred alternative to other
DTIs for ECMO patients [79, 80].
5.4. Monitoring of anticoagulation
Activated coagulation time (ACT) is the most commonly used measure of anticoagulation for
patients maintained on ECMO. Experiences extrapolated from the cardiac operating room
form the decision to use this technology for patients on ECMO. ACT is a simple, quick, and
crude measure of anticoagulation for patients on high‐dose heparin therapy (300 units/kg), but
is less reliable at standard rates of heparin infusion (<50 U/kg/h). ACT levels do not correlate
with either activated partial thromboplastin time (aPTT) or with anti‐Xa activity, especially at
lower levels of heparin dosing with ECMO [78]. Despite these limitations, ACT can be used
for patients on ECMO with goal values between 150 and 220.
Antifactor Xa assay can be used to monitor and manage unfractionated and low molecular
weight heparin therapy. Antifactor Xa levels between 0.3 and 0.7 IU/ml reflect a heparin effect;
yet, some ECMO centers advocate higher target ranges between 0.7 and 1.1 IU/ml. ACT and
antifactor Xa measure two distinct components of the coagulation process. ACT measures
whole blood clotting and is therefore affected by heparin, thrombocytopenia, and inflamma‐
tion. Antifactor Xa assay measures heparin effect or heparin concentration. Antifactor Xa assay
is specific to the anticoagulant effect of unfractionated heparin and is unaffected by coagul‐
opathy, thrombocytopenia, or dilution. aPTT is unreliable in the initial management of ECMO
patients. Once ECMO is established, aPTT can be used as a measure of anticoagulation, with
goal aPTTs between 1.5 and 2.5 times normal [81]. When comparing therapeutic ACT values
to therapeutic aPTT levels, a poor correlation exists between ACT and aPTT, and ACT testing
alone may not be enough to optimize heparin dosing [82]. Despite these limitations in ACT
monitoring, a survey of ECMO centers reported the preferred method of anticoagulation
monitoring was ACT, as reported by 97% of the respondents [54]. Most respondents reported
using more than one test to guide therapeutic decisions, with 82% utilizing AT testing, 65%
anti‐factor Xa testing, and 43% thromboelastography monitoring. Utilization of ACT to
manage ECMO patients can be complicated by limitations intrinsic to the ACT test. ACT values
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are affected by heparin therapy as well as patient characteristics, including coagulopathy,
platelet dysfunction, hypothermia, AT level, and hemodilution [78]. The use of ACT alone to
monitor the degree of anticoagulation on ECMO is too insensitive, and therefore, the addition
of other coagulation tests may prove beneficial to the patient [83]. Limited studies have been
performed with heparin concentration (Hepcon® HMS Plus, Medtronic, USA) management
in ECMO patients, and therefore target heparin concentration levels for ECMO patients are
undetermined [84]. Thrombosis and clot formation within circuits, membrane oxygenators,
and patients is a significant complication of ECMO therapy and can occur despite full
anticoagulation with heparin. Clot formation in the oxygenator is reported to occur in 13–19%,
and reported rates of serious patient complications include GI bleeding (4%), cardiac tampo‐
nade (10%), neurological events (3.5–11%), and surgical bleeding (21–24%) [78, 85].
6. Fluid management
Goals of fluid management include maintaining a normal blood volume while achieving an
adequate hematocrit and keeping a normal body weight. Blood volume should be maintained
at a level needed to maintain right atrial pressure between 5 and 10 mmHg [4]. A net negative
fluid balance should be achieved, and volume overload should be avoided as this in itself can
lead to further heart or lung injury. This balance can be difficult to achieve in patients with
capillary leakage and inflammation. Pharmacological diuretics or continuous hemofiltration
in patients with renal failure may be needed to achieve a fluid balance.
“Chattering” of the cannulas may be an indicator of intravascular volume depletion. Admin‐
istration of fluid and/or blood is indicated when this occurs. Similarly, a fluctuating flow rate
of the centrifugal pump may be due to hypovolemia, but may also occur due to excessive pump
speed or malposition of the cannulas [86].
Fluid management is also of critical importance when weaning and decannulating from
ECMO. Due to the change in the volume of distribution, fluid overload and right ventricular
failure may occur during this period [8].
7. Blood management
7.1. Transfusion thresholds
Surgical procedures in the United States account for 15 million units of packed red blood cells
(pRBCs) being transfused annually, with cardiac surgery consuming 10–15% of the U.S. blood
supply [67]. Studies in ECMO patients demonstrate even higher utilization of blood products,
most likely secondary to critical illness and alterations in hemostasis. Current transfusion
practices for cardiac surgery support transfusion when hemoglobin (Hgb) is less than 7 g/dl.
A study of 158 patients on VV and VA ECMO established that 97% of patients received
transfusions, and bleeding occurred in 17% of VV ECMO patients and 33% of VA ECMO
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patients [48]. Patients on VA ECMO received more transfused units of pRBCs than patients
on VV ECMO, and transfusion rates were higher in patients who subsequently died [48, 87,
88]. Platelet volume requirement was an independent risk factor of mortality for VV ECMO
patients, while the volume of blood transfused was an independent risk factor for mortality
on VA ECMO [48].
7.2. Red blood cells
Volume of pRBC transfused varies in ECMO patients based upon underlying indications for
support with the greatest volume transfused in cardiac patients, intermediate for eCPR
patients, and least for noncardiac indications. Volume of RBCs transfused remains an inde‐
pendent predictor of in‐hospital mortality among ECMO patients for noncardiac indications
and postcardiotomy patients [89]. A retrospective study of 38 patients on VA, VV, or VAV
ECMO, utilizing a transfusion trigger of 7 g/dl, a low dose anticoagulation strategy with a
targeted aPTT of 40–60 s and autotransfusion following decannulation demonstrated an
overall transfusion rate of 63.2% [90]. Median hemoglobin was 8.2 g/dl, and a median of 1 unit
was transfused over a median duration of 9 days. Bleeding occurred in 26.3% of patients, with
severe bleeding in 5.3%. Survival to hospital discharge occurred in 73.7%. This study suggests
a restrictive transfusion practice in critically ill patients with ARDs supported with ECMO
with a favorable and comparable outcome to studies using a higher transfusion trigger. A study
of 18 patients on VV ECMO maintained with a hemoglobin concentration between 7 and 9 g/
dl and transfused when Hgb was less than 7 g/dl demonstrated no increase in mortality (38.9%)
[91]. A restrictive transfusion approach, which is well supported in the critically ill, may also
be applicable to patients on ECMO, but large randomized control trials have not been
conducted to compare restrictive versus liberal transfusion practices.
7.3. Platelets
Initiation of ECMO causes profound changes in coagulation parameters. Platelet counts, factor
XIII, and fibrinogen all fall within the first 5 days of ECMO support, while thrombin–AT
complex, D‐dimer, and AT levels rise [92, 93]. Platelet counts typically fall during ECMO, and
remain low and only recover after cessation of ECMO therapy [92]. Platelet transfusions remain
a frequent occurrence on ECMO due to both patient factors and extracorporeal circuit factors.
Severe thrombocytopenia occurs with ECMO initiation, especially in neonates and infants.
Adults placed on ECMO post cardiotomy may have underlying thrombocytopenia and platelet
dysfunction due to recent bypass support. Some experts recommend maintaining platelet
counts between 45 and 65 × 109/l, with mandatory transfusion recommended when platelet
counts are less than 20 × 109/l [84, 93]. Thromboelastometry can help define platelet function,
and transfusion of platelets may be necessary despite a normal platelet count due to platelet
dysfunction.
7.4. Fresh frozen plasma and fibrinogen
Transfusion of clotting factors also occurs frequently to support coagulation in ECMO patients.
Maintenance of an INR less than or equal to 1.3 is recommended by transfusion guidelines.
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While FFP contains most of the clotting factors, concentrations of specific components vary
widely per unit of FFP transfused. Fibrinogen levels should be checked, and maintenance of
fibrinogen levels greater than 100 mg/dl is recommended. When supplementing fibrinogen
with cryoprecipitate, concomitant administration with platelets may increase the risk of
thrombus and thromboembolic complications. Fibrinolysis, documented by thromboelastog‐
raphy, may be treated with antifibrinolytic therapy. Treatment should be undertaken cau‐
tiously as case reports exist of fatal thrombosis associated with antifibrinolytic therapy in
ECMO patients.
7.5. AT‐III levels
Unfractionated heparin binds with AT, and this complex increases the efficacy of AT. AT levels
affect heparin PD, and measurements of AT levels can be helpful, especially in patients with
elevated unfractionated heparin requirements. Acquired AT‐III deficiency occurs commonly
during ECMO, especially in pediatric patients and can create anticoagulation issues. Supple‐
mentation of AT is currently available from three sources, if AT levels fall below 0.5–0.7 U/ml:
FFP, concentrated pooled human AT (Thrombate III®, Grifols Therapeutics, USA), and/or
recombinant AT (ATryn®, rEVO Biologics, USA). Use of Thrombate III® has been shown to
be safe in pediatric patients on ECMO without increasing bleeding complications or pRBC
transfusions [94]. Recombinant AT (rAT) has the greatest concentration among the three
products and has also been used successfully to elevate AT levels in pediatric ECMO patients.
Frequent monitoring of AT levels is recommended due to prolonged rAT pharmacokinetics
in ECMO‐supported patients [95]. In conjunction with AT supplementation, heparin dosing
should be decreased by 25% to prevent over anticoagulation. Recombinant AT is preferred
over FFP for AT supplementation in ECMO patients due to low levels of AT in FFP and
unpredictable responses to replacement with FFP. Conversion from heparin to a DTI has been
used successfully in patients with low AT‐III and concerns over supplementation with AT‐III
or FFP [68].
7.6. Recombinant factor VIIa
Concern exists for using recombinant factor VIIa (rFVIIa) on ECMO patients, despite successful
case reports for bleeding cessation, due to overwhelming patient or circuit thrombosis. A study
of 30 VA and VV ECMO patients who received recombinant factor VIIa (rFVIIa) for refractory
bleeding demonstrated an efficacy rate of 93.3% in stopping bleeding, but a patient thrombotic
rate of 3.3% and a circuit thrombotic rate of 16.7%, which were not statistically significant when
compared to controls [96]. Recombinant FVIIa should only be considered as a “last resort” to
stop bleeding in ECMO patients [67, 78, 84, 96].
7.7. Transfusion protocols
Utilization of a comprehensive ECMO anticoagulation monitoring protocol in children
can result in fewer bleeding complications, reduced blood product usage, and increased
circuit life [97].  In a small study of 10 patients using a proposed transfusion algorithm
incorporating thromboelastometry and platelet function assays, less than 20% of the
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transfusions corresponded to the algorithm, and transfusions were noted to be in excess
of those recommended [98].  This finding suggests poor adherence to algorithm‐based
transfusion practices. Consensus guidelines for blood component therapy in ECMO patients
suggest transfusing to ensure adequate oxygen carrying capacity, normal AT‐III activity
(80–120% control),  fibrinogen levels of 250–300 mg/dl,  and a platelet count greater than
80,000/μl [67].
7.8. Bloodless ECMO
Refusal of blood products by patients should not contraindicate ECMO support as a case
report describes a successful 44‐day period of ECMO support in a patient with hemoglo‐
bins between 4.5 and 6.0 g/dl who refused transfusion on religious ground [99]. A multi‐
modal approach to stimulate erythropoiesis and minimize blood loss was utilized to
manage the anemia. Another case report described a successful 15 days of bloodless VV
ECMO support in a 17‐year Jehovah's Witness patient [100]. Experience with bloodless
cardiac surgery including circuit miniaturization, reduction from the standard ECMO lab
sampling protocol, retrograde priming the ECMO circuit following cannulation, erythro‐
poietin administration, hemostasis, and cell saver reinfusion during decannulation and
separation was performed.
7.9. Thromboelastometry
Thromboelastometry [(ROTEM®, TEM/Pentapharma, Germany)(TEG®, Haemonetics,
USA)] are point of care testing devices to examine the viscoelastic properties of whole
blood. Different activators and inhibitors are utilized to examine clotting via the differ‐
ent pathways and components of the coagulation cascade. These devices evaluate from
initiation of clot formation to clot lysis and can diagnose factor deficiencies,  fibrinogen
deficiencies,  clot strength, heparin effect,  platelet function and fibrinolysis.  Interpretable
information is provided within 10 minutes with a full analysis of clot formation and lysis
within 60 minutes. Thromboelastography is however a poor guide to monitor and manage
heparin anticoagulation in ECMO patients.  A 5‐year retrospective study of 20 hepari‐
nized patients on ECMO investigated the correlation between ACT, aPTT, and thromboe‐
lastrography [101].  Analysis demonstrated poor correlation between aPTT, ACT and
INTEM clotting time with unfractionated heparin infusion rates.  Approximately 50% of
patients in this study demonstrated normal INTEM tracings despite an elevated aPTT,
questioning the sensitivity of INTEM clotting time to heparin dosing. Reliance on INTEM
clotting times only for heparin dosing could lead to heparin overdosing due to the
association of normal INTEM clotting times despite therapeutic aPTT in heparinized
ECMO patients. Thromboelastography has a role in ECMO patients, not for heparin dose
management,  but to evaluate the hemostatic balance in these complex patients.  Transfu‐
sion algorithms exist for cardiac surgery patients based upon thromboelastography patterns,
and these algorithms can be extrapolated to ECMO patients to guide medication and
transfusion therapies [98].




Prior to initiation of ECMO, lung strategies that may be undertaken beyond lung protective
ventilation include use of neuromuscular blockade [102] and/or prone positioning [103].
Another rescue therapy for patients with severe acute respiratory distress syndrome (ARDS)
and refractory hypoxemia includes high levels of positive end‐expiratory pressure (PEEP)
[104].
Whether on VV or VA ECMO, the patient's lungs should be allowed to rest and hence the
ventilator should be managed at low settings. Ventilator‐induced lung injury (VILI) also needs
to be minimized [105]. In order to reduce VILI, alveolar strain, atelectrauma, and oxygen lung
toxicity have to be prevented, and this can be achieved with ECMO [106]. According to
Extracorporeal Life Support Organization Guidelines [4], standard rest settings consist of a
low rate with a long inspiratory time, low plateau inspiratory pressure (under 25 cm H20), low
FiO2 (under 30%), and PEEP between 5 and 15 cm H2O. For patients with VV ECMO, especially
those with ARDS, tidal volume should be targeted to less than 4 ml/kg predicted body weight,
and plateau pressures should be kept ≤25 cm H2O, a concept referred to as ultraprotective
ventilation [106]. This ventilation strategy is associated with the use of high PEEP levels and
extracorporeal carbon dioxide removal (ECCO2R) [107–109]. Higher PEEP is needed in order
to prevent ventilation/perfusion mismatch [110]. High PEEP should not be used however in
patients with low lung recruitability, as this may increase alveolar strain and impair hemo‐
dynamics [111].
Manipulating ventilator settings to improve oxygenation is not recommended. Unfortunately,
the best mode of ventilation for patients on both VA and VV ECMO have yet to be determined.
Only 27% of ELSO‐registered centers have a mechanical ventilation protocol for ECMO
patients [112]. About 77% of these centers report “lung rest” to be the primary goal for
ventilation. Pressure‐controlled ventilation is the most popular mode for patients with ARDS,
and airway pressure release ventilation (APRV) is being used more in recent clinical trials [106,
113]. Specific large randomized trials that focus on mechanical ventilation with ECMO are
needed.
Monitoring the lung during ECMO can be challenging. Daily monitoring of plateau pressure,
compliance, and tidal volume may offer valuable information [106]. Transpulmonary pressure
can be estimated by an esophageal balloon in order to titrate PEEP [114].
The ventilator should be turned off in cases of interstitial emphysema or severe air leak
syndromes [4]. This will result in atelectasis, and aggressive lung recruitment will be needed
when resuming mechanical ventilation.
If the patient develops a pneumothorax during ECMO, a significant risk/benefit analysis
should be undertaken in order to decide on best management. If it is a small pneumothorax
(<20%) without hemodynamic compromise, then it is best to treat conservatively [4]. An
enlarging pneumothorax or one causing hemodynamic compromise will require external
drainage. Caution should be made in placing a chest tube, as this may lead to significant
bleeding potentially requiring a thoracotomy. A small catheter should alternatively be placed.
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The timing of tracheostomy on mechanical ventilation is controversial, with most centers
performing early tracheostomies, even though evidence has demonstrated that there is no
benefit in performing this procedure in the first 10 days on ECMO [115, 116].
Certain patients can be extubated while on ECMO and allowed to breathe spontaneously.
Awake ECMO is recommended, if possible, for patients awaiting lung transplants or suffering
from hypercapnic respiratory failure [117–119]. Also, if the patient is on VA ECMO for cardiac
support and the lungs are adequate, these patients may be extubated and managed awake.
As the patient begins to recover, lung recruitment maneuvers consisting of sustained inflation
at 25–30 cm H20 should be undertaken. In addition, sedation should be titrated to allow
spontaneous breathing while adjusting the sweep gas to maintain a PCO2 between 40 and 45
mmHg [4]. Additional lung recovery strategies include diuresis, pleural drainage, therapeutic
bronchoscopy, and positional therapy [8].
9. Conclusions
The usage of ECMO continues to evolve faster than the literature can support. Large random‐
ized trials need to be undertaken in order to support clinical practice and define best anesthetic
management. Until then, literature from other specialties such as emergency medicine and
critical care should be carefully evaluated in order to guide management of this unique patient
population.
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